Nice call! Your $96K prediction for the US price of 12 weeks of Sovaldi + Ledipasvir couldn’t possibly have been more accurate, given the pseudo disclosure on pricing that GILD just made.
In my ENTA valuation model, I’m sticking with $60K for the US ASP of ABBV/ENTA’s 3-DAA regimen, as discussed in #msg-94993406. This is a 6% discount relative to the list price of GILD’s 8-week S+L regimen and a 37.5% discount relative to the list price of GILD’s 12-week regimen. (If GILD offers significant rebates on the 8w regimen, I would expect ABBV to match them, maintaining a 5-10% discount for the ASP.)
Market Data 
Markets 
AI
